X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
regorafenib (588) 588
index medicus (291) 291
oncology (276) 276
humans (215) 215
colorectal cancer (188) 188
sorafenib (154) 154
multicenter (122) 122
chemotherapy (120) 120
cancer (111) 111
metastasis (106) 106
hepatocellular carcinoma (97) 97
pharmacology & pharmacy (95) 95
double-blind (85) 85
male (85) 85
phenylurea compounds - therapeutic use (83) 83
colorectal neoplasms - drug therapy (81) 81
female (81) 81
antineoplastic agents - therapeutic use (78) 78
bevacizumab (78) 78
pyridines - therapeutic use (78) 78
metastatic colorectal cancer (76) 76
sunitinib (74) 74
tumors (74) 74
drug therapy (70) 70
middle aged (69) 69
angiogenesis (67) 67
cancer therapies (66) 66
patients (66) 66
safety (63) 63
care and treatment (62) 62
aged (61) 61
medicine & public health (60) 60
survival (60) 60
therapy (59) 59
efficacy (58) 58
analysis (56) 56
phenylurea compounds - adverse effects (56) 56
colorectal neoplasms - pathology (55) 55
phase-3 trial (54) 54
pyridines - adverse effects (54) 54
treatment outcome (54) 54
animals (53) 53
liver cancer (53) 53
phenylurea compounds - pharmacology (52) 52
pyridines - pharmacology (51) 51
antineoplastic agents - adverse effects (50) 50
bay 73-4506 (50) 50
antineoplastic agents - pharmacology (49) 49
clinical trials (49) 49
imatinib (49) 49
adult (48) 48
phenylurea compounds - administration & dosage (46) 46
1st-line treatment (44) 44
pyridines - administration & dosage (44) 44
placebo (43) 43
review (41) 41
colorectal-cancer (40) 40
protein kinase inhibitors - therapeutic use (40) 40
kinases (39) 39
research (39) 39
apoptosis (38) 38
gastroenterology & hepatology (38) 38
gist (38) 38
cetuximab (37) 37
vascular endothelial growth factor (37) 37
aflibercept (36) 36
antineoplastic agents (36) 36
medical prognosis (36) 36
mutation (36) 36
neoplasm metastasis (36) 36
resistance (36) 36
trial (36) 36
antimitotic agents (35) 35
digestive system diseases (35) 35
endothelial growth-factor (35) 35
renal-cell carcinoma (35) 35
neoplasms. tumors. oncology. including cancer and carcinogens (34) 34
open-label (34) 34
tyrosine (34) 34
tyrosine kinase inhibitor (34) 34
prognosis (32) 32
antineoplastic agents - administration & dosage (31) 31
hypertension (31) 31
inhibitor (31) 31
liver neoplasms - drug therapy (31) 31
phase-iii (30) 30
gastrointestinal stromal tumors (29) 29
tas-102 (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
development and progression (28) 28
health aspects (28) 28
metastases (28) 28
niacinamide - analogs & derivatives (28) 28
protein kinase inhibitors - pharmacology (28) 28
ramucirumab (28) 28
cancer research (27) 27
cell biology (27) 27
expression (27) 27
growth (27) 27
protein kinase inhibitors - adverse effects (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (584) 584
French (8) 8
Russian (5) 5
German (4) 4
Japanese (4) 4
Korean (3) 3
Spanish (3) 3
Czech (2) 2
Chinese (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chinese Journal of New Drugs, ISSN 1003-3734, 10/2018, Volume 27, Issue 20, pp. 2451 - 2457
Journal Article
Oncotarget, ISSN 1949-2553, 10/2019, Volume 10, Issue 59
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 10/2019, Volume 12, Issue 3, pp. 791 - 795
Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and... 
thyroid cancer | iodine-refractory | regorafenib
Journal Article
Medicina Clinica, ISSN 0025-7753, 05/2018, Volume 150, Issue 10, pp. 390 - 397
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related... 
Liver transplant | Regorafenib | Hepatocellular carcinoma | Radioembolization | Sorafenib
Journal Article
European Journal of Cancer, ISSN 0959-8049, 12/2019, Volume 123, pp. 146 - 154
Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We... 
Regorafenib | Survival analysis | Observational study | Adverse effects
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2018, Volume 61, Issue 19, pp. 8797 - 8810
While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of... 
CHEMISTRY, MEDICINAL | IMATINIB | REGORAFENIB | HIGH-AFFINITY | SUNITINIB | MUTATIONS | SHOW | SELECTION
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2016, Volume 43, Issue 6, pp. 757 - 759
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 12/2019, Volume 81, p. 101912
Regorafenib is a multi-targeting kinase inhibitor approved for the treatment of metastatic colorectal cancer patients in refractory to standard chemotherapy.... 
Regorafenib | Biomarker | Anti-angiogenesis | Tumor microenvironment | Immunotherapy | Colorectal cancer
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 06/2019, Volume 108, Issue 6, pp. 2173 - 2179
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 45 - 56
Regorafenib (BAY 73-4506, Stivarga ) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and... 
Regorafenib | HCC | GIST | TKI | CRC
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 353 - 358
The RESORCE trial showed that regorafenib improves overall survival (OS) in patients with hepatocellular carcinoma progressing during sorafenib treatment... 
Regorafenib | Survival analysis | Treatment outcome | Hepatocellular carcinoma | Sorafenib | ADVANCED HEPATOCELLULAR-CARCINOMA | SURVIVAL | MULTICENTER | PLACEBO | SAFETY | FAILURE | THERAPY | DOUBLE-BLIND | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.